Madrid (ots/PRNewswire) - - In his Previous Position he was Vice President, Clinical Research Oncology at OSI Pharmaceuticals in the US PharmaMar announced today the appointment of Dr. Pedro Santabárbara as Senior Director of the Clinical Development Department. Dr. Santabárbara is a medical ...
Barcelona, Spain (ots/PRNewswire) - - First Inhibitor of VEGF (a) and EGF (b) Signalling to Show Anti-Tumour Activity Both as Monotherapy and in Combination With Chemotherapy AstraZeneca today reported new findings from two Phase II studies, Trials 003 and 006, in the 2nd-line treatment of NSCLC, with ...
Barcelona, Spain (ots/PRNewswire) - AstraZeneca (LSE: AZN, NYSE: AZN) announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 - now also known by its trade name, ZACTIMA (TM). Recruitment to Phase III studies evaluating the anti-tumour activity of ZACTIMA (TM) (ZD6474) ...
World Federation for Mental Health
Vienna, Austria (ots/PRNewswire) - - World Federation for Mental Health urges better understanding, treatment and management to improve outcomes for people living with bipolar disorder The World Federation for Mental Health (WFMH) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, at the World Congress of Biological Psychiatry. The survey revealed that almost half (47%) of ...
LILLE, France and MONTREAL, Québec, June 28 (ots/PRNewswire) - The latest scientific data on MacoPharma's prion filter device will be presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) being held in Athens, Greece on July 4, 2005, MacoPharma and ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI.SV) announced ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
Milwaukee and Toronto (ots/PRNewswire) - Cedara, a Merge Healthcare company (Nasdaq: MRGE), and a leading independent developer of medical software technologies for the global healthcare market, and their Distributor in the Benelux, ImaXperts BV, have finalized the installation of a new FUSION PACS(TM) for the ...
Madrid (ots/PRNewswire) - Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per share. This transaction is one of the four largest executed in European biotech in the last four years. The funds raised will be used ...
Madrid, Spain (ots/PRNewswire) - Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international institutional investors. The capital increase is expected to raise approximately one hundred (100) million euros. A "green shoe" of up to 15% of the amount raised can be exercised by ...
Copenhagen, Denmark (ots/PRNewswire) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE (European Society of Human Reproduction and Embryology) congress supports the efficacy of MENOPUR (menotrophin), a highly purified, naturally-derived infertility treatment belonging to the class of drugs known as gonadotrophins, ...
Barcelona, Spain (ots/PRNewswire) - The addition of Avastin(R) (bevacizumab, rhuMAb-VEGF) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal ...
Espoo, Finland (ots/PRNewswire) - Negotiations have been completed with the personnel representatives in Orion Diagnostica Oy, a subsidiary of Orion Corporation, concerning operational rearrangements at Orion Diagnostica's sites in Finland. As a result of the negotiations, a decision has been made to transfer the production operations of the Oulunsalo plant to Turku. There are 30 employees at the Oulunsalo site. ...
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the U.S. for Protection Against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
Frazer, Pennsylvania (ots/PRNewswire) - - Transaction Accelerates Cephalon's Entry into Oncology Market and Builds Platform for its Growing Oncology Franchise Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement with Cell Therapeutics, Inc. (Nasdaq and Nuovo Mercato: CTIC) and CTI Technologies, Inc., a wholly owned subsidiary of ...
Vienna, Austria (ots/PRNewswire) - - Data from ADEPT study showed HUMIRA slowed progression of structural joint damage Results from Abbott's Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) show that HUMIRA(R) (adalimumab) treated both joint and skin aspects of the disease and improved the quality of life measurements in patients with moderate ...
Cordis Medizinische Apparate GmbH
Miami (ots/PRNewswire) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the CYPHER(R) and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well as several other catheter-based products. Cordis intends to file an appeal with the ...
Stockholm, Sweden (ots/PRNewswire) - Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, announced that new data from a randomised, double-blind Phase 3 study demonstrate that Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg once every three weeks is at least as effective as ...
Research Triangle Park, North Carolina (ots/PRNewswire) - Quintiles Transnational Corp. today announced that Quintiles Laboratories Asia (QLAB Asia) has amended its existing agreement with Peking Union Medical College Hospital (PUMCH) to enhance central laboratory services in China. The new amended agreement with PUMCH enhances services for customers by allowing Quintiles central laboratory (QLAB) facilities in ...
Markham, Canada (ots/PRNewswire) - Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis. The study, involving 17 healthy subjects with mild to moderate plaque psoriasis, was designed to characterize the local efficacy and safety of three concentrations of CTA018. Results ...
San Diego, California (ots/PRNewswire) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has entered into an exclusive global license and co-development agreement with Novartis to develop, ...
Cranberry Township, Pennsylvania (ots/PRNewswire) - Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal ...
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
Los Angeles (ots/PRNewswire) - Infotrieve, Inc. announced today the immediate availability of the company's Life Science Research Center(TM) (LSRC), a web-based information research tool that provides scientists with one-stop search access to critical information that impacts scientific workflow. The LSRC was designed to simplify research by eliminating the need for logins to multiple information sources including ...
Indianapolis (ots/PRNewswire) - - Europe's only approved non-stimulant ADHD medication offers a new treatment choice Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of ...
Orlando, Florida (ots/PRNewswire) - - Landmark Study Big 1-98 Shows Letrozole Offers Greater Protection from Recurrence of Early Breast Cancer than Tamoxifen - Web Cast Briefing Available at 17 May 2005 8:00 AM EDT http://www.ibcsg.org/index.shtm Newly updated results of the independent Breast International Group 1-98 trial just released at ASCO show ...
Orlando, Florida (ots/PRNewswire) - Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Népszabadság, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima, have been named today by The European School of Oncology (ESO) as joint winners of the ACE (Awarding ...
Orlando, Florida (ots/PRNewswire) - - New Results Presented at ASCO Results from five clinical studies of YONDELIS (TM) (trabectedin) were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Florida, from 13-17 May 2005. YONDELIS is being developed by PharmaMar ...
Basel, Switzerland (ots/PRNewswire) - The addition of Tarceva(tm) (erlotinib) to chemotherapy extends survival by 23.5% for patients with advanced pancreatic cancer, according to data presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA.(1) Tarceva, an advanced new cancer drug taken as a once-daily tablet, has already demonstrated a clear survival benefit for patients with ...